Parsaclisib was undergoing trials for the treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.

​

Speaking to Oncologists, we had to demonstrate power, precision, and tolerability in a next-generation novel oral inhibitor.